The angiographic and clinical benefits of mibefradil in the coronary slow flow phenomenon
- 7 July 2004
- journal article
- clinical trial
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 44 (1) , 57-62
- https://doi.org/10.1016/j.jacc.2004.03.055
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Coronary hemodynamic and metabolic studies of the coronary slow flow phenomenonAmerican Heart Journal, 2003
- The Coronary Slow Flow Phenomenon – A New Coronary Microvascular DisorderCardiology, 2002
- Usefulness of oral dipyridamole therapy for angiographic slow coronary artery flowThe American Journal of Cardiology, 2001
- Metabolic interactions between mibefradil and HMG‐CoA reductase inhibitors: an in vitro investigation with human liver preparationsBritish Journal of Clinical Pharmacology, 1999
- Slow coronary flow: Clinical and histopathological features in patients with otherwise normal epicardial coronary arteriesCatheterization and Cardiovascular Diagnosis, 1996
- TIMI Frame CountCirculation, 1996
- Clinical and arteriographic characterization of patients with unstable angina without critical coronary arterial narrowing (from the TIMI-IIIA trial)The American Journal of Cardiology, 1994
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.Circulation, 1987
- Histologic evidence for small-vessel coronary artery disease in patients with angina pectoris and patent large coronary arteries.Circulation, 1986